Thermo Fisher Scientific (TMO)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$613.78-0.75%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · TMO
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $614 TMO trades at 26× p/e, below its 34× p/e peer median, but our blended $563 fair value sits below the price. It's a high-confidence read. Analysts target $490–$748. Even valued only for durable growth at sustainable margins, it's worth about $670 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $580.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $788.16 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $451.14 | — | — | Hist. CAGR | high |
| graham number | 12M | $275.94 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$490.00 – $748.00 (median $580.00) · 11 analysts · as of 2026-09-03
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 50% over what the business is worth with no growth; closing that gap needs roughly 15.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $22.49/sh owner earnings.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $163.12 |
| 18.0 |
| 14.81 |
| TTM |
| high |
| Peer P/FCF | 12M | $683.90 | 34.7 | 19.73 | TTM | high |
| Peer P/E | 12M | $807.93 | 33.9 | 23.83 | TTM | high |
| Peer P/S | 12M | $712.73 | 5.7 | 124.89 | TTM | high |
| PEG | 12M | $1352.36 | 56.8 | 23.83 | TTM | high |
| residual income | 12M | $184.83 | — | — | TTM | high |
| Own P/E history | 12M | $547.92 | 23.0 | 23.83 | TTM | high |
| triangulated | 12M | $828.37 | 33.9 | 24.43 | Triangulated | high |
| Peer P/FCF | 3Y | $854.93 | 34.7 | 24.66 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $804.60 | 33.9 | 23.73 | Analyst | medium |
| Peer P/S | 3Y | $670.48 | 5.7 | 117.49 | guidance | medium |
| PEG | 3Y | $1346.79 | 56.8 | 23.73 | Analyst | medium |
| Own P/E history | 3Y | $545.67 | 23.0 | 23.73 | Analyst | medium |
| Peer P/FCF | 5Y | $992.11 | 34.7 | 28.61 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $682.80 | 33.9 | 20.14 | Analyst | high |
| Peer P/S | 5Y | $568.99 | 5.7 | 99.71 | guidance | high |
| PEG | 5Y | $1142.92 | 56.8 | 20.14 | Analyst | high |
| Own P/E history | 5Y | $463.06 | 23.0 | 20.14 | Analyst | high |